Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
27 USD | +0.33% |
|
-0.04% | -4.20% |
06-18 | Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director | CI |
06-17 | Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.20% | 12.17B | B- | ||
+51.63% | 796B | C+ | ||
+40.70% | 628B | B | ||
-5.10% | 358B | C+ | ||
+19.90% | 331B | B- | ||
+9.95% | 301B | C+ | ||
+17.42% | 244B | B+ | ||
+3.84% | 228B | A+ | ||
+12.95% | 214B | B- | ||
+6.99% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RPRX Stock
- Ratings Royalty Pharma plc